The review found no eligible studies for this question.
The review found no eligible studies for this question.
Aldosterone antagonists probably leads to higher hyperkalaemia compared with placebo or standard care (moderate certainty).
Aldosterone antagonists showed no clear difference in hyperkalaemia compared with ACEi or ACEi plus ARB (low certainty).
Aldosterone antagonists (spironolactone or eplerenone) showed no clear difference in hyperkalaemia compared with control (placebo or standard care) (low certainty).
CHRONIC: Aldosterone antagonists may leads to higher hyperkalaemia compared with placebo (low certainty).
The review found no eligible studies for this question.
Mineralocorticoid receptor antagonists (MRAs) leads to higher hyperkalaemia compared with placebo or no treatment (high certainty).
Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in hyperkalaemia compared with selective aldosterone antagonist (low certainty).